AI and Biotech Alliance Targets Aging Diseases with New Drug Platform

SINGAPORE, PARIS and CAMBRIDGE, Mass. – March 13, 2026 – A strategic alliance between French biotechnology firm Biophytis and Singapore-based AI leader LynxKite Technologies is expanding, aiming to turbocharge the hunt for drugs that combat the ravages of aging. The partnership leverages cutting-edge artificial intelligence to discover next-generation therapies for debilitating conditions like sarcopenia and dry age-related macular degeneration (AMD), signaling a significant shift in the landscape of longevity medicine.

This expanded collaboration builds on their initial MASSIVE project and is set to develop a computational longevity platform designed to identify and validate new drug candidates at a pace far exceeding traditional methods. The initiative has garnered support from Enterprise Singapore, aligning with the nation's ambitious RIE 2030 plan to establish itself as a global biotech powerhouse.

The AI Engine Redefining Discovery

The core of the collaboration is LynxKite's sophisticated AI platform, which integrates graph analytics and generative AI to navigate the immense complexity of biological data. Unlike traditional linear analysis, graph-based AI excels at modeling intricate networks of relationships, such as how genes, proteins, and molecules interact within the body. This allows researchers to uncover novel insights into disease mechanisms and identify promising drug targets that might otherwise remain hidden.

LynxKite, whose founding team has advised over 100 global firms including pharmaceutical giants Roche and AstraZeneca, brings state-of-the-art software engineering and chemoinformatics to the table. Its platform harnesses the massive parallel processing power of the latest NVIDIA GPU toolkits and neoclouds like Nebius to run complex computational pipelines. This AI-driven engine can design and screen millions of potential drug molecules in silico (on a computer), prioritizing only the most promising candidates for expensive and time-consuming laboratory synthesis and testing.

This acceleration is a game-changer in an industry where development timelines can span over a decade and costs can exceed a billion dollars per drug. The project aims to create a continuous feedback loop, where the AI's predictions are tested in the lab, and the real-world biological data is then used to further refine and improve the AI models.

"We are proud to collaborate with Biophytis on pioneering computational longevity through our LynxKite platfom, which demonstrates how LynxKite can revolutionize discovery by designing, integrating and orchestrating relevant computational tools in diverse modalities," said Gyorgy Lajtai, CEO of LynxKite.

Targeting the Unseen Enemies of Aging

The partnership is initially focused on two conditions that represent enormous unmet medical needs for the world's aging population. Sarcopenia, the degenerative loss of muscle mass and strength, affects millions of elderly individuals, leading to frailty, falls, and a profound loss of independence. Despite its prevalence, there are currently no approved pharmacological treatments, creating a market projected to reach USD 5.6 billion by 2032.

The alliance will also target dry age-related macular degeneration, the leading cause of irreversible vision loss in older adults. While recent breakthroughs have produced the first-ever treatments for the advanced stage of dry AMD, known as geographic atrophy, a vast need remains for therapies that can halt or reverse the disease in its earlier stages. The global market for dry AMD therapeutics is already substantial, valued at over USD 10 billion and expected to nearly double within the next decade.

The scientific lynchpin of the initial project is the Mas receptor (MasR). This receptor is part of a protective pathway in the body that has anti-inflammatory and regenerative effects. Biophytis has deep expertise in this area, with its lead drug candidate, BIO101, being a MasR activator that has shown promise in Phase 2 trials for sarcopenia. The new AI platform will now be tasked with discovering entirely new, next-generation molecules that can activate this same protective pathway with even greater efficacy and precision.

"The launch of MASSIVE marks a decisive step in our longevity strategy, combining our clinical expertise with LynxKite's innovative AI to accelerate the discovery of transformative therapies against sarcopenia," stated Stanislas Veillet, CEO of Biophytis.

Singapore's Bid for Global Biotech Leadership

The support from Enterprise Singapore is more than a simple endorsement; it places this partnership at the heart of a national strategy. Singapore's Research, Innovation and Enterprise (RIE) 2030 plan is a multi-billion-dollar government initiative designed to cement the city-state's position as a world-class hub for science and technology. With a recently announced budget of S$37 billion for the next five years, the plan heavily prioritizes human health, potential, and longevity.

By backing the Biophytis-LynxKite collaboration, Singapore is fostering a powerful synergy. It attracts a European clinical-stage biotech with deep domain expertise (Biophytis) and pairs it with a homegrown AI champion (LynxKite) that is already a global leader in its field. This model not only accelerates innovation but also builds a robust local ecosystem, creating high-value jobs and anchoring intellectual property within Singapore's borders.

A High-Stakes Gamble on a New Frontier

Despite the immense promise of AI, the path from a computer-generated molecule to an approved, patient-ready drug remains long and challenging. Biophytis, like many clinical-stage biotechs, operates in a high-risk, high-reward environment, relying on successful clinical data and strategic financing to advance its pipeline. The company is currently securing funding and partnerships to launch a large-scale Phase 3 trial for its lead candidate in sarcopenia.

The collaboration with LynxKite represents a calculated bet that technology can significantly de-risk and shorten this arduous journey. By filtering out likely failures early and optimizing candidates for success, the AI platform aims to improve the odds dramatically. If the alliance succeeds, it could provide Biophytis with a pipeline of next-generation assets, solidifying its position in the longevity space.

For millions of people worldwide facing the prospect of muscle wasting and vision loss, the stakes are even higher. This fusion of biology and artificial intelligence represents a new front in the fight against age-related disease, offering a potent source of hope that science and technology can extend not just lifespan, but healthspan.